Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ther Adv Med Oncol
Hoofdauteurs: Lee, Min-Sang, Cho, Hee Jin, Hong, Jung Yong, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Cho, Yong Beom, Kim, Seung Tae
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publications 2020
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/
https://ncbi.nlm.nih.gov/pubmed/33224274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items